Cite
HARVARD Citation
Bellini, A. et al. (2021). Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of clinical oncology. 39 (30), pp. 3377-3390. [Online].